Skip to contentC
Cannabis Bioscience International Holdings, Inc.
C
CBIHCannabis Bioscience International Holdings, Inc. Q2 2026 · 10-Q
Revenue$53.27K$53.27K−28.3% vs Q2 2025 Net Income-$116.97K-$116.97KN/M vs Q2 2025 EPS Diluted-$0.00-$0.00N/M vs Q2 2025 Gross Profit$42,766−35.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cannabis Bioscience International Holdings, Inc. · CIK 1411057 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,493N/M Margins · derivedGross margin80.3%−9.2 pt vs Q2 2025
Operating margin-180.0%−99.7 pt vs Q2 2025
Net margin-219.6%−112.5 pt vs Q2 2025
ended Nov 30, 2025 · filed Feb 19, 2026 · 81 d after period end